ArticleJournal of advanced research2026
NLRP6 governs hippocampal microglial phagocytosis to resist stress-induced depressive-like behaviors in mice and the intervention effect of bezafibrate.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microglial Alkbh5 Deficiency Alleviates Chronic Restraint Stress-Induced Depression-like Behaviors in Mice.Neuroscience bulletin · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMicroglial phagocytosis is crucial for maintaining central nervous system (CNS) homeostasis and is implicated in the development of depression. NOD-like receptor family pyrin domain containing 6 (NLRP6) represents a potential target for depression treatment, but underlying mechanisms remain unclear. Bezafibrate has been shown to exhibit multiple neuroprotective effects.
objectivesTo investigate the effects of NLRP6 on microglial phagocytosis and depressive-like behaviors, elucidate the potential underlying mechanisms, and evaluate bezafibrate's therapeutic impact.
methodsNLRP6 complete gene knockout (Nlrp6-KO), microglia-conditional knockout (Nlrp6-cKO), and chronic restraint stress (CRS) model were established in mice. Behavioral tests (OFT, TST, FST, SPT) were used to assess depressive-like behaviors. Fluorescently labeled cellular debris was stereotactically injected into the hippocampus or co-cultured with the BV2 microglial cell line to assess the microglial phagocytic activity. Underlying mechanisms were investigated using RNA-seq, luciferase assays, flow cytometry, Western blot, qPCR, and ELISA.
resultsEnriched NLRP6 expression in microglia was confirmed by RNAscope experiment. Nlrp6-KO and Nlrp6-cKO mice exhibited significant depressive-like behaviors, accompanied by impaired microglial phagocytic function. In the BV2 cells, NLRP6 regulated phagocytosis of cellular debris by promoting the transactivation of cluster differentiation 36 (CD36). More importantly, corticosterone inhibited NLRP6 and its target gene CD36 expression, thereby reducing microglial phagocytosis. However, bezafibrate treatment restored the NLRP6-CD36 axis, enhanced microglial phagocytosis, and suppressed the inflammatory response to cellular debris in BV2 cells. In CRS mice, bezafibrate alleviated depressive-like behaviors, reversed NLRP6/CD36 downregulation, improved phagocytosis, and reduced hippocampal neuroinflammation. Importantly, bezafibrate failed to alleviate depressive-like behaviors in Nlrp6-KO mice, indicating NLRP6 is essential for its antidepressant effect.
conclusionNLRP6 critically regulates microglial phagocytosis via CD36, combating depression. Bezafibrate alleviates stress-induced depressive behaviors and neuroinflammation primarily by enhancing NLRP6-dependent phagocytosis. Thus, NLRP6 represents a promising therapeutic target in hippocampal microglia for maintaining CNS homeostasis and treating depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.